
Loading, please wait...

Loading, please wait...

Atopic dermatitis (AD) is a significant health concern for infants across the globe. Consequently, experts are prioritizing atopic dermatitis prevention to reduce the long-term psychosocial and financial burden on families. Recent reviews of clinical trials published between 2020 and 2025 suggest that specific interventions during early infancy may offer protective benefits. Specifically, researchers are evaluating the efficacy of moisturizers and probiotics as primary tools for risk reduction.
Moisturizers have historically shown mixed results in preventing eczema. However, new evidence from the 2025 CASCADE trial indicates that daily emollient application from nine weeks of age can significantly reduce AD incidence by two years. Furthermore, this study suggests that even infants not selected for high genetic risk can benefit from regular barrier support. In contrast, earlier meta-analyses warned of potential increases in skin infections, highlighting the need for careful application techniques.
Additionally, probiotics represent a promising \"inside-out\" approach to prevention. Recent systematic reviews demonstrate that oral probiotic supplementation during pregnancy and early infancy may reduce AD risk by approximately 26%. This benefit likely stems from the modulation of the gut-skin axis, which helps regulate the developing immune system. Nevertheless, trial heterogeneity and varying probiotic strains make it difficult to establish a universal protocol for all patients.
While these interventions show potential, firm conclusions remain elusive. Doctors must consider the heterogeneity of trial designs and the varying definitions of AD used in research. Moreover, clinical effects are often relatively small or inconsistent across different populations. Therefore, healthcare providers should personalize prevention strategies based on individual risk factors and family history.
Recent evidence suggests that daily moisturizer use from early infancy may reduce the incidence of AD, particularly by supporting the skin barrier. However, results vary between high-risk and general populations.
Probiotic supplementation during pregnancy and infancy may reduce the risk of developing atopic dermatitis by influencing the gut-skin axis. Current research indicates a potential risk reduction of around 26%.
Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.
References
1. Kiszluk A et al. The State of Prevention of Atopic Dermatitis: An Updated Review. Pediatr Dermatol. 2026 Feb 22. doi: 10.1111/pde.70157. PMID: 41723876.
2. Simpson E et al. Emollients to Prevent Pediatric Eczema: A Randomized Clinical Trial. JAMA Dermatol. 2025 Jul 23. doi:10.1001/jamadermatol.2025.2357.
3. Sulejmani et al. Prevention of Atopic Dermatitis: What Are We Missing? PMC. 2025 Jul 22.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A comprehensive review of clinical trials from 2020-2025 evaluating moisturizers and probiotics for the primary prevention of atopic dermatitis in infants....
5 months ago

A post hoc analysis of the 3-year SURMOUNT-1 trial shows that tirzepatide 15 mg significantly reduces predicted 10-year cardiovascular disease risk (ARR -1.31%, HR 0.62) compared to placebo in adults with obesity and prediabetes, offering durable primary cardiovascular prevention.
Today

A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
Today

A systematic review and meta-analysis of 21 RCTs reveals that exercise snacks significantly improve VO2max and peak power output in adults. While aerobic gains were strongest in adults under 50, power output improved across all ages. Evidence for blood lipids and body fat changes remains inconsistent.
Today

A ten-year review highlights how preclinical time-lapse micro-CT and synchrotron imaging allow dynamic tracking of cortical bone porosity and remodeling space kinetics. Recent studies reveal how therapeutic agents like PTH and glucocorticoids alter linear erosion rates and pore morphology.
Today

A study demonstrates that gomisin N (25 µM) protects MIN6 pancreatic beta-cells by alleviating endoplasmic reticulum and oxidative stress induced by CPA. By reducing ROS levels and promoting correct proinsulin folding, gomisin N restores insulin secretion and beta-cell viability in diabetes models.
Today